Shanghai North Carolina's wholly-owned acquisition of Anhui Zhongwang Jianfeng Pharmaceutical API Base is beginning to take shape.
Release time:
2020-08-14
Shanghai Beika's wholly-owned acquisition of Anhui Zhongwang
Jianfeng Pharmaceutical Raw Material Drug Base is showing its embryonic form
News from our newspaper 8# October 3 , Shanghai Beika Pharmaceutical Technology Co., Ltd., a holding subsidiary of Jianfeng Pharmaceutical, signed an equity transfer agreement with shareholders of Anhui Zhongwang Pharmaceutical Co., Ltd, it is proposed to invest ,2062 yuan to acquire all 100% shares of the company. This is another important move to build a production base for API after the acquisition of equity in Shanghai North Carolina at the beginning of the year.
Anhui Zhongwang is located in Xiangyu Chemical Park, Dongzhi County, Chizhou City, Anhui Province. It is a pharmaceutical intermediate manufacturing enterprise integrating R & D, production and sales, focusing on characteristic medicines, intermediates, new materials, etc. R & D, production and sales of fine chemicals. The main business activities are the production and sales of 92% potassium hydrogen fluoride and 8% potassium fluoride mixture, ethyl acetate, aqueous DMF , aqueous triethylamine, toluene, methanol, acetic acid, DMF , triethylamine, industrial sodium chloride, chemical products (except hazardous chemicals and explosives); Research and development of biopharmaceuticals, chemical raw materials, pharmaceutical intermediates and fine chemicals. The company has two ofloxacin carboxylic acid production lines with a total production capacity of 1200 tons / years, and its supporting safety, environmental protection, storage and management systems, and has passed ISO9001 : 2015 quality management system certification, ISO14001 : 2015 environmental management system certification, OHSAS18001 : 2015 occupational health and safety management system certification and safety three-level standardization construction; the main products, oxyfluorocarboxylic acid, levooxyfluorocarboxylic acid and levooxyfluorocarboxylic acid, passed the on-site audit of well-known domestic pharmaceutical enterprises, levofluorocarboxylic acid passed the on-site audit of Indian pharmaceutical enterprises, and 2017 12 received the on-site audit of the process verification of oxyfluorocarboxylic acid by U.S. pharmaceutical enterprises. It is hoped that it has been registered in U.S. document DMF as a supplier of raw material.
The equity acquisition of Anhui Zhongwang is an important measure to strengthen the development of the pharmaceutical business sector according to the company's strategic policy of "strengthening the main business through cooperation and innovation, standardizing science and seeking development. After the acquisition, Anhui Zhongwang will become a wholly-owned subsidiary of Shanghai Beika. The company plans to use the factory building and construction land of Anhui Zhongwang to plan the construction of pharmaceutical intermediates and API projects, which is conducive to the overall layout of Jianfeng Pharmaceutical's chemical API base in Anhui: the pesticide and primary pharmaceutical intermediates will be arranged in the factory area of Anhui Xinbeika Chemical Co., Ltd., and the API and advanced pharmaceutical intermediates will be arranged in the factory area of Anhui Zhongwang, it can make full use of Anhui Zhongwang's factory area, public engineering facilities, quality management system and other advantages to speed up the construction progress of Jianfeng Pharmaceutical Anhui Chemical Raw Material Drug Base. In addition, the acquisition of Anhui Zhongwang will also help expand the R & D, production and sales of Shanghai North Carolina's existing fine chemicals business such as intermediates and new materials, further extend and improve the industrial chain, and consolidate its market position. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page